The role of environmental agents in Parkinson's disease

Clinical Neuroscience Research

Volumn 1, Issue 6, 2001, Pages 419-426

  Di Monte, Donato A ^a  

^a PARKINSON S INSTITUTE   (United States)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Dopamine; Metal; Neurodegeneration; Neurotoxin; Pesticide; Synuclein

Indexed keywords

EID: 0012678765     PISSN: 15662772     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1566-2772(01)00020-2     Document Type: Review

References (69)

1. Tanner CM, Ottman R, Goldman SM, et al. Parkinson disease in twins: an etiologic study. J Am Med Assoc 1999;281:341-346.
2. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000;3:1301-1306.
3. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
4. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998;18:106-108.
5. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 1998;95:6469-6473.
6. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980.
7. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 1983;80:4546-4550.
8. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 1985;82:2173-2177.
9. Gainetdinov RR, Fumagalli F, Jones SR, Caron MG. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem 1997;69:1322-1325.
10. Daniels AJ, Reinhard Jr JF. Energy-driven uptake of the neurotoxin 1-methyl-4-phenylpyridinium into chromaffin granules via the catecholamine transporter. J Biol Chem 1988;263:5034-5036.
11. Takahashi N, Miner LL, Sora I, et al. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion and enhanced MPTP toxicity. Proc Natl Acad Sci USA 1997;94:9938-9943.
12. Graham DG. On the origin and significance of neuromelanin. Arch Pathol Lab Med 1979;103:359-362.
13. D'Amato RJ, Alexander GM, Schwartzman RJ, Kitt CA, Price DL, Snyder SH. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity. Nature 1987;327:324-326.
14. Liou HH, Tsai MC, Chen CJ, et al. Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology 1997;48:1583-1588.
15. Marder K, Logroscino G, Alfaro B, et al. Environmental risk factors for Parkinson's disease in an urban multiethnic community. Neurology 1998;50:279-281.
16. Morano A, Jimenez-Jimenez FJ, Molina JA, Antolin MA. Risk-factors for Parkinson's disease: case-control study in the province of Caceres, Spain. Acta Neurol Scand 1994;89:164-170.
17. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 1998;50:1346-1350.
18. Semchuk KM, Love EL, Lee RG. Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurology 1993;43:1173-1180.
19. Fall PA, Fredrikson M, Axelson O, Granerus AK. Nutritional and occupational factors influencing the risk of Parkinson's disease: a case-control study in southeastern Sweden. Mov Disord 1999;14:28-37.
20. Gorell JM, Johnson CC, Rybicki BA, et al. Occupational exposures to metals as risk factors for Parkinson's disease. Neurology 1997;48: 650-658.
21. Kuhn W, Winkel R, Woitalla D, Meves S, Przuntek H, Muller T. High prevalence of parkinsonism after occupational exposure to lead-sulfate batteries. Neurology 1998;50:1885-1886.
22. Pezzoli G, Strada O, Silani V, et al. Clinical and pathological features in hydrocarbon-induced parkinsonism. Ann Neurol 1996;40:922-925.
23. Hageman G, van der Hoek J, van Hout M, et al. Parkinsonism, pyramidal signs, polyneuropathy, and cognitive decline after long-term occupational solvent exposure. J Neurol 1999;246:198-206.
24. Gorell JM, Rybicki BA, Johnson CC, Peterson EL. Smoking and Parkinson's disease: a dose-response relationship. Neurology 1999;52:115-119.
25. Elbaz A, Manubens-Bertran JM, Baldereschi M, et al. Parkinson's disease, smoking, and family history. J Neurol 2000;247:793-798.
26. Paganini-Hill A. Risk factors for Parkinson's disease: the leisure world cohort study. Neuroepidemiology 2001;20:118-124.
27. Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. J Am Med Assoc 2000;283:2674-2679.
28. Hellenbrand W, Seidler A, Boeing H, et al. Diet and Parkinson's disease. I: A possible role for the past intake of specific foods and food groups. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology 1996;47:636-643.
29. Janson AM, Moller A. Chronic nicotine treatment counteracts nigral cell loss induced by a partial mesodienchephalic hemitransection: an analysis of the total number and mean volume of neurons and glia in substantia nigra of the male rat. Neuroscience 1993;57:931-941.
30. Minana MD, Montoliu C, Llansola M, Grisolia S, Felipo V. Nicotine prevents glutamate-induced proteolysis of the microtubule-associated protein MAP-2 and glutamate neurotoxicity in primary cultures of cerebellar neurons. Neuropharmacology 1998;37:847-857.
31. Fowler JS, Volkow ND, Wang GJ, et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature 1996;379:733-736.
32. Khalil AA, Steyn S, Castagnoli Jr N. Isolation and characterization of a monoamine oxidase inhibitor from tobacco leaves. Chem Res Toxicol 2000;13:31-35.
33. 18F]6-fluorodopa PET. J Neurol 2000;247(Suppl 2):II110-II113.
34. Di Monte DA, Sandy MS, Ekstrom G, Smith MT. Comparative studies on the mechanisms of paraquat and 1-methyl-4-phenylpyridine (MPP +) cytotoxicity. Biochem Biophys Res Commun 1986;137:303-309.
35. Corasaniti MT, Strongoli MC, Rotiroti D, Bagetta G, Nistico G. Paraquat: a useful tool for the in vivo study of mechanisms of neuronal cell death. Pharmacol Toxicol 1998;83:1-7.
36. Perry TL, Yong VW, Wall RA, Jones K. Paraquat and two endogenous analogues of the neurotoxic substance N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine do not damage dopaminergic nigrostriatal neurons in the mouse. Neurosci Lett 1986;69:285-289.
37. Di Monte DA, McCormack AL, Langston JW, Thiruchelvam M, Cory-Slechta DA. Paraquat-induced dopaminergic cell loss in the mouse substantia nigra. Toxicologist 2001;60:238.
38. Corsini GU, Pintus S, Chiueh CC, Weiss JF, Kopin IJ. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice is enhanced by pretreatment with diethyldithiocarbamate. Eur J Pharmacol 1985;119:127-128.
39. Walters TL, Irwin I, Delfani K, Langston JW, Janson AM. Diethyldithiocarbamate causes nigral cell loss and dopamine depletion with nontoxic doses of MPTP. Exp Neurol 1999;156:62-70.
40. Heikkila RE, Cabbat FS, Cohen G. In vivo inhibition of superoxide dismutase in mice by diethyldithiocarbamate. J Biol Chem 1976;251:2182-2185.
41. Irwin I, Wu EY, DeLanney LE, Trevor A, Langston JW. The effect of diethyldithiocarbamate on the biodisposition of MPTP: an explanation for enhanced neurotoxicity. Eur J Pharmacol 1987;141:209-217.
42. Bachurin SO, Shevtzova EP, Lermontova NN, Serkova TP, Ramsay RR. The effect of dithiocarbamates on neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and on the mitochondrial respiration chain. Neurotoxicology 1996;17:897-903.
43. Vaglini F, Fascetti F, Fornai F, Maggio R, Corsini GU. (+)MK-801 prevents the DDC-induced enhancement of MPTP toxicity in mice. Brain Res 1994;668:194-203.
44. McGrew DM, Irwin I, Langston JW. Ethylenebisdithiocarbamate enhances MPTP-induced striatal dopamine depletion in mice. Neurotoxicology 2000;21:309-312.
45. Thiruchelvam M, Richfield EK, Baggs RB, Tank AW, Cory-Slechta DA. The nigrostriatal dopaminergic system as a preferred target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J Neurosci 2000;20:9207-9214.
46. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990;54:823-827.
47. Marey-Semper I, Gelman M, Levi-Strauss M. The high sensitivity to rotenone of striatal dopamine uptake suggests the existence of a constitutive metabolic deficiency in dopaminergic neurons from the substantia nigra. Eur J Neurosci 1993;5:1029-1034.
48. Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci 1985;36:2503-2508.
49. Fleming L, Mann JB, Beann J, Briggle T, Sanchez-Ramos JR. Parkinson's disease and brain levels of organochlorine pesticides. Ann Neurol 1994;36:100-103.
50. Corrigan FM, Murray L, Wyatt CL, Shore RF. Diorthosubstituted polychlorinated biphenyls in caudate nucleus in Parkinson's disease. Exp Neurol 1998;150:339-342.
51. Sanchez-Ramos J, Facca A, Basit A, Song S. Toxicity of dieldrin for dopaminergic neurons in mesencephalic cultures. Exp Neurol 1998;150:263-271.
52. Miller GW, Kirby ML, Levey AI, Bloomquist JR. Heptachlor alters expression and function of dopamine transporters. Neurotoxicology 1999;20:631-637.
53. Pal PK, Samii A, Calne DB. Manganese neurotoxicity: a review of clinical features, imaging and pathology. Neurotoxicology 1999;20:227-238.
54. Witholt R, Gwiazda RH, Smith DR. The neurobehavioral effects of subchronic manganese exposure in the presence and absence of pre-parkinsonism. Neurotoxicol Teratol 2000;22:851-861.
55. Pezzoli G, Ricciardi S, Masotto C, Mariani CB, Carenzi A. n-Hexane induces parkinsonism in rodents. Brain Res 1990;531:355-357.
56. Sengstock GJ, Olanow CW, Menzies RA, Dunn AJ, Arendash GW. Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers. J Neurosci Res 1993;35:67-82.
57. Degli Espositi M. Inhibitors of NADH-ubiquinone reductase: an overview. Biochem Biophys Acta 1998;1364:222-235.
58. Nagatsu T, Yoshida M. An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions. Neurosci Lett 1988;87:178-182.
59. Collins MA, Neafsey EJ. Beta-carboline analogues of N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): endogenous factors underlying idiopathic parkinsonism? Neurosci Lett 1985;55:179-184.
60. Herrero MT, Hirsch EC, Kastner A, et al. Neuromelanin accumulation with age in catecholaminergic neurons from Macaca fascicularis brainstem. Dev Neurosci 1993;15:37-48.
61. Pakkenberg H, Andersen BB, Burns RS, Pakkenberg B. A stereological study of substantia nigra in young and old rhesus monkeys. Brain Res 1995;693:201-206.
62. Bus JS, Gibson JE. Paraquat: model for oxidant-initiated toxicity. Environ Health Perspect 1984;55:37-46.
63. Hensley K, Pye QN, Maidt M, et al. Interaction of alpha-phenyl-N-tert-butyl nitrone and alternative electron acceptors with complex I indicates a substrate reduction site upstream from the rotenone binding site. J Neurochem 1998;71:2549-2557.
64. Vila M, Vukosavic S, Jackson-Lewis V, Neystat M, Jakowec M, Przedborski S. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J Neurochem 2000;74:721-729.
65. Forloni G, Bertani I, Calella AM, Thaler F, Invernizzi R. Alpha-synuclein and Parkinson's disease: selective neurodegenerative effect of alpha-synuclein fragment on dopaminergic neurons in vitro and in vivo. Ann Neurol 2000;47:632-640.
66. Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000;287:1265-1269.
67. Lee M, Hyun D, Halliwell B, Jenner P. Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J Neurochem 2001;76:998-1009.
68. da Costa CA, Ancolio K, Checler F. Wild-type but not Parkinson's disease-related ala-53 → Thr mutant alpha-synuclein protects neuronal cells from apoptotic stimuli. J Biol Chem 2000;275:24065-24069.
69. Kholodilov NG, Neystat M, Oo TF, et al. Increased expression of rat synuclein in the substantia nigra pars compacta identified by mRNA differential display in a model of developmental target injury. J Neurochem 1999;73:2586-2599.